Interestingly, in a prior study, GPR84-deficient mice developed reduced hepatic steatosis compared to wildtype mice [13], supporting a metabolic disease-promoting role of MCFA-GPR84 signaling in the context of NAFLD. This evidence concerns the gene GPR84 and fatty liver disease.